ArticlePLoS neglected tropical diseases2010
Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops.
Article in PLoS neglected tropical diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Comparison of Methods for Assessing Chlamydia trachomatis Transmission Intensity: A Systematic Review.The American journal of tropical medicine and hygiene · 2026Article
- Assessing the prevalence of trachoma in the East, North, Far North and Adamaoua regions of Cameroon, 2016-2022.International health · 2025Article
- The eye as the discrete but defensible portal of coronavirus infection.The ocular surface · 2021Review
- Effectiveness and safety of azithromycin 1.5% eye drops for mass treatment of active trachoma in a highly endemic district in Cameroon.BMJ open ophthalmology · 2020Article
- Antioxidants and vision health: facts and fiction.Molecular and cellular biochemistry · 2014Review
- The limits of medical interventions for the elimination of preventable blindness.Tropical medicine and health · 2014Article
- Will the SAFE strategy be sufficient to eliminate trachoma by 2020? Puzzlements and possible solutions.TheScientificWorldJournal · 2013Review
- Azithromycin reduces inflammation in a rat model of acute conjunctivitis.Molecular vision · 2013Article
- Prevalence of trachoma in the Far North region of Cameroon: results of a survey in 27 Health Districts.PLoS neglected tropical diseases · 2013Article
- Contributions to the Improvement of Living Conditions among Neglected Populations with Trachoma.Tropical medicine and health · 2012Article
- Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis.Drugs · 2012Review
- Review of Azithromycin Ophthalmic 1% Solution (AzaSite(®)) for the Treatment of Ocular Infections.Ophthalmology and eye diseases · 2012Article
- Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite) solution in the treatment of ocular infections.Clinical ophthalmology (Auckland, N.Z.) · 2011Article
- An eye for azithromycin: review of the literature.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFollowing an epidemiological study carried out in 2006 showing a high prevalence of blinding trachoma in the Far North Region of Cameroon, a trachoma elimination programme using the SAFE strategy was initiated: three yearly trachoma mass treatments were to be performed. METHODOLOGY/PRINCIPAL
findingsThe entire district population (120,000 persons) was treated with azithromycin 1.5% eye drops in February 2008 and January 2009. To assess the effect of treatment on the prevalence of active trachoma, three epidemiological studies were conducted on a representative sample of children aged between 1 and 10 years. The first study was performed just prior to the first treatment, the second just prior to the 2nd treatment and the third one, one year later. The prevalence of active forms of trachoma (TF + TI) dropped from 31.5% (95%CI 26.4-37.5) before treatment to 6.3% (95%CI 4.1-9.6) one year after first treatment; a reduction of nearly 80%. One year after the second treatment, the prevalence decreased to 3.1% (95%CI 2.0-4.9), a total reduction of 90%. Furthermore, there were no more TI cases (only TF). There was no report of serious or systemic side effects. Tolerance was excellent. CONCLUSIONS/SIGNIFICANCE: Active trachoma mass treatment with azithromycin 1.5% eye drops is feasible, well tolerated, and effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.